Clinical Trial Update: Boost Study 21270 (Cognition) [EARLY_Phase 1]

View source ↗

Summary

NXTech's early-phase Boost Study 21270 in cognition has completed its Phase 1 trial, with results posted in December 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Snippet

Sponsor: NXTech | Conditions: Cognitive Function Abnormal | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2024-12-18